Introduction: the heart as an endocrine organ
In the classical model, the heart is a pump: four chambers, valves, myocardium, and the conduction system. This model works for mechanics, but it is physiologically incomplete. Since 1981, it has been known that the heart is a fully functional endocrine organ that synthesizes its own family of hormones.
In 1981, de Bold and colleagues found that injection of atrial extract caused potent diuresis and natriuresis in rats (de Bold AJ, Life Sci 1981, PMID 7242086). This discovery changed the understanding of cardiovascular regulation: the heart itself synthesizes a diuretic and vasodilator, antagonizing the renin-angiotensin-aldosterone system (RAAS).
Key idea of the md_pereligyn protocol: natriuretic peptides are an endogenous pharmacopoeia that works 24/7 without tablets. Their concentration and receptor sensitivity are modifiable parameters. NT-proBNP in a routine laboratory is a window into this system.
Understanding the peptide factory shifts cardiology from “pump repair” to “endocrine regulation.”
🌀
The natriuretic peptide family
Three key peptides:
▸ANP (atrial natriuretic peptide) — synthesized by atrial cardiomyocytes in response to wall stretch. Its action is acute, over minutes. It stimulates diuresis, natriuresis, and vasodilation. ▸BNP (brain natriuretic peptide) — despite its name, because it was first isolated from porcine brain, its main source is the cardiac ventricles. Synthesis increases with ventricular overload. Its action is longer-lasting. ▸CNP (C-type natriuretic peptide) — produced by the endothelium and chondrocytes. It is a local paracrine regulator of vascular tone and bone growth.
All three act through NPR-A and NPR-B receptors, activating guanylate cyclase and increasing intracellular cGMP. The final effects are vasodilation and natriuresis.
Peptide degradation occurs through neutral endopeptidase (neprilysin) and the NPR-C clearance receptor. Modern ARNI-class drugs (sacubitril/valsartan) inhibit neprilysin, extending the life of the patient’s own peptides (McMurray JJV, NEJM 2014, PMID 25176015).
🌀
Physiology of action
Natriuretic peptides are RAAS antagonists. They work in the opposite direction to angiotensin II and aldosterone.
▸Natriuresis — increased sodium excretion in the distal tubules through inhibition of reabsorption. ▸Diuresis — increased urine volume through suppression of ADH and direct tubular effects. ▸Vasodilation — relaxation of arteriolar smooth muscle via cGMP. ▸RAAS suppression — reduced renin and aldosterone secretion. ▸Sympathetic suppression — reduced central sympathetic activity. ▸Antifibrotic effect — suppression of myocardial myofibroblast proliferation. ▸Lipolysis — stimulation of visceral fat breakdown through the NPR-A receptor on adipocytes. In lean patients, BNP levels are higher than in patients with obesity under comparable hemodynamic load.
The obesity paradox: in obesity, NT-proBNP is underestimated by 30–50% relative to the true cardiac load. This masks early heart failure and requires BMI adjustment during interpretation.
🌀
When the heart increases synthesis
Stimuli that increase ANP/BNP synthesis:
•Wall stretch — the main trigger. Volume overload (hypervolemia, valvular regurgitation) or pressure overload (hypertension, aortic stenosis). •Heart failure — sustained NT-proBNP elevation is a diagnostic marker. •Acute ischemia — myocardial infarction increases BNP within 24–48 hours. •Arrhythmias — atrial fibrillation and tachycardia increase ANP. •Hypoxia — sleep apnea, COPD, pulmonary hypertension. •Acute physical exercise — a short-term physiological rise. •Pregnancy — physiological increase in the third trimester.
Stimuli that reduce synthesis or bioavailability:
•Obesity — increased clearance via NPR-C on adipocytes. •Young age and male sex — lower basal levels. •High-dose glucocorticoids — suppression of synthesis.
🌀
Biomarkers and diagnostic windows
Two main biomarkers are available in clinical practice:
▸NT-proBNP — the N-terminal fragment of proBNP. Half-life 60–120 min. Stable during collection and storage. Target ranges: • <125 pg/mL (age <75 years) — heart failure is unlikely • 125–450 pg/mL — gray zone, requires clinical interpretation • >450 pg/mL (<50 years), >900 (50–75), >1800 (>75) — high probability of HF ▸BNP — the biologically active peptide. Half-life 20 min. Less stable during storage. Target <100 pg/mL; >400 pg/mL — high probability of HF.
Other biomarkers:
▸MR-proANP (mid-regional proANP) — a stable proANP fragment. An alternative to NT-proBNP. ▸hsTnT / hsTnI (high-sensitivity troponin) — a marker of myocardial microinjury. Combined with NT-proBNP, it provides a more complete picture. ▸ST2 (soluble suppression of tumorigenicity 2) — a marker of fibrosis and remodeling. Prognostically independent of NT-proBNP. ▸Galectin-3 — myocardial fibrosis. A prognostic marker in chronic heart failure.
When to order NT-proBNP:
▸Dyspnea of unclear origin, to differentiate cardiogenic from pulmonary causes ▸Lower-extremity edema ▸Fatigue and reduced exercise tolerance ▸Hypertension with suspected occult HF ▸Screening in metabolic syndrome and type 2 diabetes ▸Before major surgery to assess cardiovascular risk ▸Monitoring chronic HF therapy — NT-proBNP reduction correlates with prognosis
🌀
Holistic protocol for supporting the peptide factory
Principle of the md_pereligyn protocol: the natriuretic system is a modifiable resource. Holistic work supports synthesis, receptor sensitivity, and clearance.
### 1. Reduction of visceral obesity
▸Weight loss of 5–10% — increases basal BNP and improves NPR-A receptor sensitivity. ▸Mediterranean / DASH pattern — olive oil, fish, vegetables, legumes. Reduction of visceral fat stores. ▸Strength training 2–3 times/week — support of muscle mass and metabolic flexibility. ▸Intermittent fasting 14:10 / 16:8 — improvement in HOMA-IR and reduction in fat mass.
### 2. Control of arterial hypertension
▸Target BP <130/80 — reduces chronic myocardial overload and stabilizes BNP within the physiological range. ▸Full hypertension protocol — see [the BP article](/blog/blood-pressure-drivers-holistic-protocol). ▸Addressing sleep apnea — nocturnal hypoxia and BP surges load the atria and ventricles.
### 3. Aerobic exercise
▸Walking 7–10 thousand steps/day — sustained physiological stimulation of BNP synthesis and increased receptor sensitivity. ▸Aerobic activity 30+ minutes/day — swimming, cycling. Acute BNP rise during exercise and resting adaptation. ▸HIIT 1–2 times/week — in cardiovascularly stable patients, improves VO2max and myocardial remodeling.
### 4. Omega-3 EPA+DHA
▸EPA+DHA 2 g/day — reduction of pressure overload, antifibrotic effect, and support of cardiomyocyte membranes. ▸Check the omega-3 index every 4–6 months, target >8%. ▸Quality is critical: fish oil should be tested for oxidation (TOTOX <26).
### 5. Magnesium and taurine
▸Magnesium (glycinate / taurate) 400 mg/day — a cofactor for cGMP synthesis and a direct vascular relaxant. ▸Taurine 1–3 g/day — modulation of cardiomyocyte calcium homeostasis and cardioprotection in chronic HF. ▸Potassium 4–5 g/day through diet — leafy greens, avocado, legumes.
### 6. CoQ10 and mitochondrial support
▸Ubiquinol (CoQ10) 100–200 mg/day — a cofactor for myocardial oxidative phosphorylation. In patients with chronic HF, it reduces mortality (Mortensen SA, JACC Heart Fail 2014, PMID 25282031). ▸L-carnitine 1–2 g/day — transport of fatty acids into mitochondria. ▸D-ribose 5–10 g/day — a substrate for ATP synthesis when ejection fraction is reduced.
### 7. Vitamin D and K2
▸Vitamin D3 to a level of 50–80 ng/mL, with doses of 2,000–5,000 IU/day individualized. ▸Vitamin K2 (MK-7) 100–200 mcg — directs calcium into bone and protects against valve and vascular calcification.
### 8. Sleep and parasympathetic tone
▸Sleep 7–9 hours — a window for hormonal recovery and restoration of receptor sensitivity. ▸Breathing practices 10–20 min/day — slow diaphragmatic breathing (6 cycles/min) reduces preload. ▸HRV biofeedback — increase in parasympathetic tone.
🌀
What does NOT work
▸Ignoring NT-proBNP in obesity — underestimation by 30–50%. BMI adjustment is mandatory. ▸Isolated diuretic use without addressing the cause — reduces preload but does not solve the root cause of HF. ▸Chronic high-dose NSAID use — inhibits prostaglandins, increases sodium retention, and antagonizes peptides. ▸Chronic sleep deprivation and stress — increase sympathetic tone and RAAS activity, antagonizing the peptide system. ▸Isolated CoQ10 use without correcting hypertension and obesity — fragmented effect. ▸Self-discontinuation of ARNI / ACE inhibitors in chronic HF — abrupt withdrawal can cause decompensation.
🌀
When to seek care
▸Dyspnea with minimal exertion or at rest ▸Lower-extremity edema, especially in the evening ▸Nocturnal cough, orthopnea (needing to sit upright to breathe) ▸Fatigue and abrupt reduction in exercise tolerance ▸NT-proBNP >125 pg/mL (or above age-adjusted thresholds) ▸Previous myocardial infarction or atrial fibrillation ▸Family history of chronic HF or sudden cardiac death ▸Type 2 diabetes duration >10 years — screening for occult HF
I perform comprehensive cardiovascular screening (NT-proBNP, hsTnT, echocardiography with functional assessment, extended metabolic profile) and create a personalized protocol to support the natriuretic system.
🌀
Conclusion
The heart is an endocrine organ. Atrial and ventricular cardiomyocytes synthesize the natriuretic peptides ANP and BNP, the body’s own diuretic and vasodilator that antagonizes RAAS. This is an endogenous pharmacopoeia working 24/7.
NT-proBNP in a routine laboratory is a window into this system. A target level <125 pg/mL (with age adjustment) indicates preserved function. Elevation is an early signal of occult heart failure long before clinical symptoms appear.
The holistic protocol — reduction of visceral obesity, BP control, aerobic exercise, omega-3, magnesium, taurine, CoQ10, vitamin D + K2, and sleep — supports synthesis and receptor sensitivity. ARNI-class drugs extend the life of the patient’s own peptides, illustrating how modern pharmacology copies endogenous physiology.
Treatment should target regulation, not only symptoms.
🌀
Sources
▸de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. *Life Sci* 1981;28:89–94. PMID 7242086 ▸Levin ER, Gardner DG, Samson WK. Natriuretic peptides. *NEJM* 1998;339:321–328. PMID 9682046 ▸McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *NEJM* 2014;371:993–1004. PMID 25176015 ▸Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO. *JACC Heart Fail* 2014;2:641–649. PMID 25282031 ▸Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2016;37:2129–2200. PMID 27206819 ▸Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. *J Am Coll Cardiol* 2022;79:e263–e421. PMID 35379503
Related articles: [Endothelium: foundation of vascular health](/blog/endothelium-foundation-vascular-health), [Cholesterol without statins](/blog/cholesterol-without-statins).
🌀
FAQ
What does NT-proBNP show in practice? NT-proBNP is the most sensitive laboratory marker of heart failure. A level <125 pg/mL (age <75 years) makes HF unlikely, with high negative predictive value. Exceeding age-adjusted thresholds requires echocardiography and assessment of cardiac structure. The marker is also used to monitor therapy — a reduction in NT-proBNP during treatment is associated with improved prognosis.
Why can NT-proBNP be normal in a patient with obesity despite obvious HF? Adipocytes express NPR-C clearance receptors, which accelerate peptide removal from the blood. In patients with BMI >35, NT-proBNP is underestimated by 30–50% relative to the true cardiac load. Interpretation uses BMI adjustment or additional markers (MR-proANP, echocardiography).
Can endogenous natriuretic peptides be “boosted” without drugs? Yes, partially. Aerobic exercise, reduction of visceral fat, omega-3, magnesium, taurine, and BP control improve receptor sensitivity and support synthesis. ARNI drugs (sacubitril/valsartan) inhibit peptide degradation and prolong their half-life — they act on a molecule the body already synthesizes.
When should a healthy person order NT-proBNP? In dyspnea of unclear origin, edema, occult HF in the setting of diabetes or hypertension, before major surgery, or with a family history of chronic HF before age 60. Routine screening is not indicated in a young healthy person without symptoms. In metabolic syndrome or type 2 diabetes lasting >10 years, it is justified.
What is the difference between ARNI and a standard ARB? ARNI (sacubitril/valsartan) combines a neprilysin inhibitor, which increases levels of endogenous natriuretic peptides, with an ARB, which blocks angiotensin II. In PARADIGM-HF, cardiovascular death was reduced by 20% versus enalapril (McMurray 2014, PMID 25176015). This is an example of targeted amplification of an endogenous system rather than replacement of it.
*This article is for informational purposes only and is not a substitute for professional medical advice. Discuss any nutraceutical, medication adjustment, or diagnostic procedure with your treating physician before starting.*
